JP2015511618A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511618A5
JP2015511618A5 JP2015502351A JP2015502351A JP2015511618A5 JP 2015511618 A5 JP2015511618 A5 JP 2015511618A5 JP 2015502351 A JP2015502351 A JP 2015502351A JP 2015502351 A JP2015502351 A JP 2015502351A JP 2015511618 A5 JP2015511618 A5 JP 2015511618A5
Authority
JP
Japan
Prior art keywords
vesicle
preparation
use according
surfactant
sulfolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511618A (ja
Filing date
Publication date
Priority claimed from GBGB1205642.0A external-priority patent/GB201205642D0/en
Application filed filed Critical
Publication of JP2015511618A publication Critical patent/JP2015511618A/ja
Publication of JP2015511618A5 publication Critical patent/JP2015511618A5/ja
Pending legal-status Critical Current

Links

JP2015502351A 2012-03-29 2013-03-28 小胞製剤 Pending JP2015511618A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1205642.0 2012-03-29
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
PCT/EP2013/056694 WO2013144289A1 (en) 2012-03-29 2013-03-28 Vesicular formulations

Publications (2)

Publication Number Publication Date
JP2015511618A JP2015511618A (ja) 2015-04-20
JP2015511618A5 true JP2015511618A5 (enExample) 2016-05-26

Family

ID=46159988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502351A Pending JP2015511618A (ja) 2012-03-29 2013-03-28 小胞製剤

Country Status (19)

Country Link
US (1) US9555051B2 (enExample)
EP (1) EP2830630A1 (enExample)
JP (1) JP2015511618A (enExample)
KR (1) KR20150004798A (enExample)
CN (1) CN104349782A (enExample)
AU (1) AU2013241701A1 (enExample)
BR (1) BR112014024033A8 (enExample)
CA (1) CA2867749A1 (enExample)
CL (1) CL2014002547A1 (enExample)
CO (1) CO7121334A2 (enExample)
EA (1) EA038899B1 (enExample)
GB (2) GB201205642D0 (enExample)
IL (1) IL234747A0 (enExample)
IN (1) IN2014DN07913A (enExample)
MX (1) MX2014011516A (enExample)
NZ (1) NZ700472A (enExample)
PH (1) PH12014502065A1 (enExample)
SG (1) SG11201406144TA (enExample)
WO (1) WO2013144289A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232034A1 (en) 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
BR112017013471A2 (pt) * 2014-12-23 2018-02-27 Camurus Ab Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
ES2879383T3 (es) 2015-06-30 2021-11-22 Sequessome Tech Holdings Limited Fórmulas mixtas
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
EP4297743A1 (en) * 2021-02-25 2024-01-03 Exinov Emulsion for use in the treatment of rosacea

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
EP0238554A4 (en) 1985-09-27 1987-10-27 Univ California SYSTEM FOR TRANSDERMAL DELIVERY OF MEDICAMENTS TO LIPOSOMES.
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
DE59307395D1 (de) 1992-07-08 1997-10-23 Dianorm G Maierhofer Gmbh Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
DK1032379T3 (da) * 1997-11-19 2002-04-02 Schering Ag Præparat med azelainsyre
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
AU9740498A (en) 1998-09-01 2000-03-21 Idea Ag Electrically controlled transport of charged penetrants across barriers
CN1320880C (zh) 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
ES2295149T3 (es) 2000-04-12 2008-04-16 Liplasome Pharma A/S Sistemas de suministro de farmacos contra infecciones parasiticas.
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
WO2002062316A1 (de) 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
HUP0600294A2 (en) 2001-05-31 2007-02-28 Pharmacia Corp Skin-permeable selective cyclooxygenase-2 inhibitor composition
WO2003000190A2 (en) 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
ES2411656T3 (es) 2002-03-13 2013-07-08 Thomas SKÖLD Sistemas de administración a base de agua
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
EP1815847A3 (en) 2002-10-11 2008-11-05 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
US20070160656A1 (en) 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
EP1658086A2 (en) 2003-07-21 2006-05-24 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
EP1811961A2 (en) 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
BRPI0615411A2 (pt) 2005-08-29 2012-12-04 Sepsicure L L C uso de um ácido da bìlis ou de um sal de ácido da bìlis e um fosfolipìdeo
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
CN101541308B (zh) 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
WO2010090654A1 (en) 2009-02-05 2010-08-12 Tdt, Ltd. Methods of reducing the proliferation and viability of microbial agents
CN105434354A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
US20120232034A1 (en) * 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
HK1221412A1 (zh) 2013-07-31 2017-06-02 Sequessome Technology Holdings Limited 囊泡

Similar Documents

Publication Publication Date Title
JP2017105763A5 (enExample)
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
WO2013114371A8 (en) Dry powder formulations of dnase i
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
CO6640250A2 (es) Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2015184127A3 (en) Stable cannabinoid formulations
WO2017091739A8 (en) Topical film-forming spray
NZ631100A (en) Soft chewable pharmaceutical products
JP2012255026A5 (enExample)
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2015048757A3 (en) Foam formulations and apparatus for delivery
WO2012083138A3 (en) Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
PH12020550864A1 (en) Vesicles for delayed delivery of fragrance their preparation and use thereof
MX2015007824A (es) Formulaciones parasiticidas transdermicas.
JP2015521599A5 (enExample)
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
HK1221412A1 (zh) 囊泡
MX384159B (es) Formulaciones y métodos para el suministro vaginal de antiprogestinas.
NZ719321A (en) Storage stable lyophilized tripeptide formulations
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
JP2016538288A5 (enExample)